Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28345166 | 1.00 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL653032 | 0.98 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL22999868 | 0.96 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14157163 | 0.84 | KDM4E (0.35) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL28780551 | 0.81 | — | — | |
| SCHEMBL415009 | 0.81 | MAPT (0.43) | KDM4EHSD17B10KMT2A | |
| SCHEMBL16097451 | 0.81 | MAPK1 (0.36) | KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL443973 | 0.80 | MAPT (0.44) | KDM4EHSD17B10KMT2A | |
| SCHEMBL14964749 | 0.79 | TLR4 (0.33) | — | |
| SCHEMBL4060101 | 0.76 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541634-B2 | Reacting a pyrazolo(4,3-a)pyridine compound with amine | PFIZER INC. | 2003-04-01 | — | — | US | claimed |
| US-20250206884-A1 | ULTRAVIOLET RADIATION-CURABLE POLYSILOXANE COMPOSITION, AND DAMPING MATERIAL | TAICA CORPORATION (JP) | 2025-06-26 | — | — | US | disclosed |
| WO-2025011546-A1 | HUMAN CASEINOLYTIC PROTEASE P AGONISTS AND USES THEREOF | ACELON THERAPEUTICS (CN) | 2025-01-16 | — | — | WO | disclosed |
| CN-118974144-A | Ultraviolet-curable polysiloxane composition and damping material | 株式会社泰已科 | 2024-11-15 | — | — | CN | disclosed |
| CN-117229280-A | Method for preparing capromorelin | 洛阳惠中兽药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| WO-2023189433-A1 | ULTRAVIOLET RADIATION-CURABLE POLYSILOXANE COMPOSITION, AND DAMPING MATERIAL | 株式会社タイカ | 2023-10-05 | — | — | WO | disclosed |
| CN-115844895-A | Use of an emiritone compound for the preparation of a medicament for the treatment of central nervous system cancer | 昂克希尔迪克斯有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-109311980-B | G protein-coupled receptor (GPCR) modulation by emilienone (IMIPRIDONES) | 昂克希尔迪克斯有限公司 | 2023-01-17 | — | — | CN | disclosed |
| EP-0812196-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1997-12-17 | — | — | EP | disclosed |
| WO-1997024369-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1996025934-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-08-29 | — | — | WO | disclosed |
| EP-0551509-A1 | PHOTOGRAPHIC MATERIAL AND PROCESS | EASTMAN KODAK COMPANY (US) | 1993-07-21 | — | — | EP | disclosed |
| US-5075488-A | Fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-12-24 | — | — | US | disclosed |
| EP-0128006-B1 | A SOIL-DISEASE-CONTROLLING AGENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-4709052-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-11-24 | — | — | US | disclosed |
| EP-0128006-A2 | A soil-disease-controlling agent | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-12-12 | — | — | EP | disclosed |
| US-4440940-A | HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-04-03 | — | — | US | disclosed |
| US-4230878-A | AND 4-(UNSATURATED ALKYL)AMINOBENZOIC ACIDS AND DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CLPP, PRCP, PREP | CHRNB2 3717/4885CHRNA4 4170/4885CHRNB4 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.